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Martin Hofmann-ApitiusAbstract
The “big data” paradigm has gained a lot of attention recently, in particular in those areas of biomedicine where
we face clear unmet medical needs. Coined as a new paradigm for complex problem solving, big data
approaches seem to open promising perspectives in particular for a better understanding of complex diseases
such as Alzheimer’s disease and other dementias. In this commentary, we will provide a brief overview on big
data principles and the potential they may bring to dementia research, and - most importantly - we will do a
reality check in order to provide an answer to the question of whether dementia research is ready for big data
approaches.
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According to Wikipedia, “Big data is a broad term for
data sets so large or complex that traditional data pro-
cessing applications are inadequate. Challenges include
analysis, capture, data curation, search, sharing, storage,
transfer, visualization, and information privacy. The term
often refers simply to the use of predictive analytics or
other certain advanced methods to extract value from
data, and seldom to a particular size of data set” [1].
The wide use of the term has contributed to its fuzzi-
ness, and the usual IT marketing Newspeak has done its
part, too. However, in the original definition by the Gart-
ner group [2] there are three aspects that constitute “big
data”; we will use them for the discussion of big data in
dementia research. Big data is characterized by:
 Volume of data. The “data flood” that we
experience in biomedicine, for example, through the
enhanced capabilities in the area of genome and
transcriptome sequencing technologies, but also in
the area of neuroimaging and clinical data
 Velocity of data. Usually this “V” is associated with
the processing of real-time data analysis (for example,
from sensor networks or online trading), but in itsCorrespondence: martin.hofmann-apitius@scai.fraunhofer.de
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creativecommons.org/publicdomain/zero/1.0/core, this concept also covers the heterogeneity of
data with respect to time scales.
 Variety of data. This is the most interesting aspect
of big data when it comes to biomedicine. Linking
heterogeneous data is a key step in big data
analytics, and shared semantics for metadata
annotation play an important role in data
integration.
A fourth aspect has recently been added to the big
data concepts; it covers the issue of heterogeneous data
quality and the need for curation:
 Veracity of data. This concept deals with the need
for quality assessment, pre-processing, and curation
of data. This is of particular importance in biomedi-
cine, where the quality of data and annotations var-
ies in wide ranges.
Given the complexity of neurodegenerative diseases, it
is not surprising that we observe a significant heterogen-
eity of data in that scientific area. Heterogeneity of data
concerns their mode (omics data, imaging data, clinical
data → variety) as well as their quality (as determined
by statistics criteria and with respect to available meta-
data → veracity). Big data analytics makes use of a
wide range of data integration, modeling, and miningess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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havior in complex systems. The expectations on com-
plex problem solving capabilities that come with big
data approaches are high in the research community
working on dementia. As a first big data challenge in
Alzheimer’s research, the DREAM challenge has been
launched recently [3].
Promising advances, but a reality check is needed
Big data approaches differ substantially from established
biostatistics approaches. Whereas biostatisticians try to
keep the number of variables low and put great effort
into controlling the experiment, big data analytics ac-
cepts as a fundamental premise the heterogeneity of data
with respect to both quality and type. Big data ap-
proaches try to understand complex systems and try to
overcome problems with lacking data by a virtuosic
combination of data, knowledge, and imputation of
missing values. Interoperability of data and knowledge is
key to big data approaches and, therefore, shared seman-
tics (for example, controlled vocabularies; ontologies)
play a crucial role not only for metadata annotation, but
also for data integration and information extraction pro-
cedures. In dementia research, we deal with a wide range
of data coming from different levels: omics technologies
produce large amounts of quantitative data (such as
gene expression data) or qualitative data (for example,
single nucleotide polymorphism, SNP, data); neuroimag-
ing generates huge amounts of imaging data that require
complex image analysis workflows to extract features
from images that can be used in integrative modeling
and mining approaches. Dementia research is therefore
inherently multi-modal (having different modes of data
acquisition) and multi-scalar (ranging from the molecu-
lar scale (omics) to the organism (neuroimaging; clinical
and cognitive data) and population scales (epidemio-
logical data)).
A reality check of the current situation in dementia
with respect to the adoption of big data principles leads
us to the DREAM challenge, the first data analytics chal-
lenge in the area of research on Alzheimer’s disease [3].
The tasks in this challenge were highly relevant for
current Alzheimer’s research, but not too complex and
aimed at identifying those features that were informative
for the prediction of “cognitive scores 24 months after
initial assessment” (subchallenge 1); to “predict the set
of cognitively normal individuals whose biomarkers are
suggestive of amyloid perturbation” (subchallenge 2);
and to “classify individuals into diagnostic groups using
MR images” (subchallenge 3).
The data sets made available for the DREAM chal-
lenge did not bring along the challenge to harmonize
and curate them across different scales or modes of
measurement. In that respect, the DREAM challenge onAlzheimer’s disease was not truly a big data challenge. It
was rather a statistical quantitative data mining exercise
without a decent biological context or knowledge com-
ponent to integrate. However, attempts to collect and to
centrally provision research data in the dementia arena
(neuGrid4you [4]; AETIONOMY [5]; Alzheimer’s & De-
mentia knowledge resource [6]) force us to pay much
more attention to the most important V’s: V(ariety) and
V(eracity). Over the last three years, our team has spent
considerable effort on the quality assessment and cur-
ation of all publicly available omics data in the area of
neurodegenerative diseases. In order to represent the
relevant knowledge in a computable form, we and other
groups have generated models of disease [7, 8] that rep-
resent a good part of the knowledge about Alzheimer’s
and Parkinson’s diseases and make this knowledge
amenable for computer-based reasoning approaches [9].
Together with curated omics data and additional efforts
on clinical data, these models form the basis for the
most comprehensive knowledge base on neurodegenera-
tive diseases, the AETIONOMY knowledge base [10].
This knowledge base will support future big data ap-
proaches in dementia research by harmonized annotations
across heterogeneous data sets and tight integration of
disease models, literature-based knowledge, and primary
experimental data. Other resources that are currently be-
ing built include the AMP AD partnership [11]; a dedi-
cated topic on big data in Alzheimer’s research can be
found on the website indicated in Ref. [12].
Future trends and emerging technologies
A spectrum of currently emerging technologies will add
to the V(olume) of data relevant for dementia research:
next-generation sequencing (NGS) and in particular
RNAseq technologies will generate high-quality gene ex-
pression data; epigenetics studies in the dementia con-
text will add an entire level of new information. Patient-
specific iPS cells will be analyzed simultaneously for
gene expression, epigenetics mechanisms, and proteo-
mics (including pathway regulation). More data will also
be generated at the clinical level: large observational
studies (such as the Rhineland Study conducted by the
German National Dementia Research Center [13]) will
produce huge amounts of clinical and imaging data. The
interpretation of data generated at various different levels
and including data that come from either cell and tissue
cultures or animal models will require new approaches for
integrative data analysis. Big data principles will therefore
become even more relevant for integrative modeling and
mining and any sort of “systems approach” in dementia
research. The computable Alzheimer’s disease model
shown in Fig. 1 (a model representing cause-and-effect re-
lationships under disease conditions) captures and repre-
sents knowledge about disease processes in Alzheimer’s
Fig. 1 Alzheimer’s disease model encoded in OpenBEL with zoom presentation of the major pathology mechanisms (tau, APP)
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pretation of big data in the Alzheimer’s research area.Conclusions
We can expect that, in the near future, data production at
all levels - from the omics level to the clinical and popula-
tion level - will increase with the same rate in dementia
research that we can observe in other indication areas.
The need for increased interoperability of data (and know-
ledge!) will simultaneously increase, and substantial effort
will be required to cope not only with the rapid growth of
data volume, but also with the notorious lack of interoper-
ability of data, information, and knowledge. We will see
more ambitious mining scenarios in big data challenges in
the future, and there is no doubt: integrative modeling
and mining approaches will come, and they will have a
strong impact on dementia research.Competing interests
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